您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Silicristin
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Silicristin
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Silicristin图片
CAS NO:33889-69-9
包装:20mg
市场价:1386元

产品介绍
Silicristin 是一种丰富的黄酮木脂素,存在于水飞蓟的果实中,具有抗氧化特性。
Cas No.33889-69-9
别名水飞蓟汀
化学名(2R,3R)-3,5,7-trihydroxy-2-[(2R,3S)-7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydro-1-benzofuran-5-yl]-2,3-dihydrochromen-4-one
Canonical SMILESCOC1=C(C=CC(=C1)C2C(C3=C(O2)C(=CC(=C3)C4C(C(=O)C5=C(C=C(C=C5O4)O)O)O)O)CO)O
分子式C25H22O10
分子量482.44
溶解度≥ 24.6mg/mL in DMSO
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Silychristin is an abundant flavonolignan present in the fruits of Silybum marianum, with antioxidant properties. Silychristin is a potent inhibitor of the thyroid hormone transporter MCT8, and elicits a strong inhibition of T3 uptake with an IC50 of 110 nM[1][2].

Silychristin exhibits a strong inhibition of MCT8-mediated T3 uptake with an IC50 of 110 nM in MCT8 overexpressing MDCK1-cells[2].Silychristin causes no cytotoxic for fibroblasts[3].Silychristin (6.5-75 μM; 24 hours) diminishes UVA toxicity and reduces ROS generation, and the protective effect is dose-dependent[3].Silychristin (12.5μM, 25μM) reduces the metalloproteinase-1 (MMP-1) level in cells[3].

References:
[1]. Biedermann D, et al. Silychristin: Skeletal Alterations and Biological Activities. J Nat Prod. 2016 Dec 23;79(12):3086-3092.
[2]. Johannes J, et al. Silychristin, a Flavonolignan Derived From the Milk Thistle, Is a Potent Inhibitor of the Thyroid Hormone Transporter MCT8. Endocrinology. 2016 Apr;157(4):1694-701.
[3]. Rajnochová Svobodová A, et al. A pilot study of the UVA-photoprotective potential of dehydrosilybin, isosilybin, silychristin, and silydianin on human dermal fibroblasts. Arch Dermatol Res. 2019 Aug;311(6):477-490.